SNY

Teva and Sanofi reported positive 44‑week data for duvakitug in ulcerative colitis and Crohn’s disease. The announcement came from Teva’s affiliate and Sanofi.

In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44Duvakitug was well tolerated and safety was consistent with the induction study PARSIPPANY, N.J. and PARIS, Oct.

Duvakitug maintained high rates of clinical remission, response, and endoscopic improvement at week 44 in ulcerative colitis. In Crohn’s disease it also kept high rates of endoscopic and clinical response.

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany.

Recursion Pharmaceuticals is in focus after positive drug data and a Sanofi milestone. The company’s funding mix and dilution profile have changed with recent equity and milestone deals.